Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Huntsman Cancer Institute (University of Utah)

Sites in Salt Lake City, UT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1139
Shown on this page
12
Current sort
Recently updated
Campus scope
Huntsman Cancer Institute (University of Utah), Salt Lake City, UT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Huntsman Cancer Institute (University of Utah), Salt Lake City, UT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 673–684 of 1,139 matching trials with a site at Huntsman Cancer Institute (University of Utah), Salt Lake City, UT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

NCT04281485
Site status not listed — check the official record
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
PF-06939926, Placebo
Genetic · Other
Lead sponsor
Pfizer
Industry
Eligibility
4 Years to 7 Years · Male only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2039
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Phase 2 Interventional

Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

NCT05143840
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid, Leukemia,Myeloid, Chronic
Interventions
Single Agent Asciminib, Low TKI, Elective Free Treatment
Drug · Combination Product · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Phase 3 Interventional

FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)

NCT04768972
Site status not listed — check the official record
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ION363, Placebo
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
10 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
8
States / cities
La Jolla, California • Palo Alto, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With Phenylketonuria

NCT05270837
Site status not listed — check the official record
View directory record Official record
Conditions
Phenylketonuria (PKU)
Interventions
Pegvaliase, Diet Only
Drug · Other
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
12 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
Site status not listed — check the official record
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Recruiting Phase 2Phase 3 Interventional

Superiority Trial of Aphasia-focused Rehabilitation With tDCS Stimulation

NCT07688551
Status at this site: Recruiting
View directory record Official record
Conditions
Aphasia, Broca's Aphasia
Interventions
tDCS
Device
Lead sponsor
University of South Carolina
Other
Eligibility
25 Years to 80 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Charleston, South Carolina • Columbia, South Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

NCT06649110
Status at this site: Recruiting
View directory record Official record
Conditions
Healthy Volunteers, Pulmonary Arterial Hypertension
Interventions
LTP, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Orange, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Digital Health Implementation Strategies to Improve Lung Cancer Screening Among Safety-Net Clinics

NCT07716280
Status at this site: Recruiting
View directory record Official record
Conditions
Lung Cancer
Interventions
Text Messages (TM+), Chat bot (CA), Video, Reactive Patient Navigation (RPN), Proactive Patient Navigation (PPN)
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
50 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Not applicable Interventional

Healthy Opioid Prescription Engagement

NCT05141266
Site status not listed — check the official record
View directory record Official record
Conditions
Opioid Misuse, Opioid-Related Disorders, Pharmacist-Patient Relations
Interventions
Patient Navigation, Standard Medication Counseling (SMC)
Behavioral · Other
Lead sponsor
Jerry Cochran
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

NCT04970901
Site status not listed — check the official record
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Relapsed B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
Interventions
Loncastuximab Tesirine, Polatuzumab Vedotin, Glofitamab, Mosunetuzumab, Obinutuzumab
Drug
Lead sponsor
ADC Therapeutics S.A.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
24
States / cities
Clovis, California • San Diego, California • Miami, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 5, 2026, 10:22 AM EST
Recruiting Phase 3 Interventional

Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement

NCT06033599
Status at this site: Recruiting
View directory record Official record
Conditions
Polysubstance Abuse, Opioid Use, Tobacco Use
Interventions
MORE and MI and NRT, MORE and No MI and NRT, Support Group and MI and NRT, Support Group and No MI and NRT
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
New Brunswick, New Jersey • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 5, 2026, 10:22 AM EST

About this Huntsman Cancer Institute (University of Utah) institution page

What this page lists
ClinicalTrials.gov records that list Huntsman Cancer Institute (University of Utah) in Salt Lake City, UT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.